Do we have to change therapeutic considerations in peripheral arterial disease?

被引：1
|
作者：
Berent, Robert [1 ]
Sinzinger, Helmut [2 ]
机构：
[1] HerzReha Bad Ischl, Ctr Cardiovasc Rehabil, Bad Ischl, Austria
[2] Inst Diag & Treatment Lipid Disorders & Atheroscl, Vienna, Austria
来源：
VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE | 2018年 / 47卷 / 01期
关键词：
ANTIPLATELET THERAPY; ATRIAL-FIBRILLATION; ASPIRIN; RIVAROXABAN; PREVENTION; EVENTS; METAANALYSIS; CLOPIDOGREL; EFFICACY; SAFETY;
D O I：
10.1024/0301-1526/a000673
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：5 / 6
页数：2
相关论文
共 50 条
  • [21] Growth factors for therapeutic angiogenesis in peripheral arterial disease
    Jones, William S.
    Annex, Brian H.
    CURRENT OPINION IN CARDIOLOGY, 2007, 22 (05) : 458 - 463
  • [22] Pharmacotherapy for peripheral arterial disease: Emerging therapeutic options
    Jaff, MR
    ANGIOLOGY, 2002, 53 (06) : 627 - 633
  • [23] Education therapeutic for the treatment of patients with peripheral arterial disease
    Piotrkowska, Renata
    Dobosz, Marek
    Halena, Grzegorz
    Ksiazek, Janina
    PIELEGNIARSTWO CHIRURGICZNE I ANGIOLOGICZNE-SURGICAL AND VASCULAR NURSING, 2011, (01): : 13 - 17
  • [24] The role of platelets in peripheral arterial disease: Therapeutic implications
    Matsagas, MI
    Geroulakos, G
    Mikhailidis, DP
    ANNALS OF VASCULAR SURGERY, 2002, 16 (02) : 246 - 258
  • [25] Medical management of peripheral arterial disease: A therapeutic algorithm
    Lumsden, AB
    Rice, TW
    JOURNAL OF ENDOVASCULAR THERAPY, 2006, 13 : 19 - 29
  • [26] Therapeutic potentials of natriuretic peptides for peripheral arterial disease
    Park, Kwijun
    Itoh, Hiroshi
    Yamahara, Kenich
    Sone, Masakatsu
    Miyashita, Kazutoshi
    Oyamada, Naohumi
    Sawada, Naoya
    Taura, Daisuke
    Inuzuka, Megumi
    Tamura, Naohisa
    Fukunaga, Yasutomo
    Nakao, Kazuwa
    JOURNAL OF HYPERTENSION, 2006, 24 : 184 - 184
  • [27] Contributions to understanding therapeutic change: Now we have a playground
    Harrison, Alexandra M.
    Tronick, Edward Z.
    JOURNAL OF THE AMERICAN PSYCHOANALYTIC ASSOCIATION, 2007, 55 (03) : 853 - 874
  • [28] Do We Have to Change the Way Targeted Drugs Are Developed?
    Ocana, Alberto
    Amir, Eitan
    Seruga, Bostjan
    Pandiella, Atanasio
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (24) : E420 - E421
  • [29] DO WE HAVE TO CHANGE OUR ATTITUDE TOWARDS TESTING
    THEISEN, D
    KAUTSCHUK GUMMI KUNSTSTOFFE, 1990, 43 (04): : 273 - 274
  • [30] Congenital myelomeningocele - do we have to change our management?
    Mayer S.
    Weisser M.
    Till H.
    Gräfe G.
    Geyer C.
    Cerebrospinal Fluid Research, 7 (1):
12345